grant
HIV Tat and Opiate-mediated aberrations in glial-neuronal crosstalk: Implications for the role of extracellular RNA in HAND
Organization UNIVERSITY OF NEBRASKA MEDICAL CENTERLocation OMAHA, UNITED STATESPosted 1 Jul 2024Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2026AIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAffectAmmon HornAnti-Retroviral AgentsAssayAstrocytesAstrocytusAstrogliaAutophagocytosisBioassayBiological AssayBody TissuesBrainBrain Nervous SystemCNS Nervous SystemCell BodyCell CommunicationCell InteractionCell-to-Cell InteractionCellsCentral Nervous SystemChemosensitizationChemosensitization/PotentiationChemotactic CytokinesCognitive DisturbanceCognitive ImpairmentCognitive declineCognitive function abnormalCommon Rat StrainsConfocal MicroscopyCornu AmmonisCoupledDLG4DLG4 geneDataDevelopmentDiseaseDisease ProgressionDisorderDisturbance in cognitionDown-RegulationDropsDrug Use DisorderDrug usageDrugsEncephalonEngineeringEpidemicExcitatory SynapseExposure toFrequenciesFunctional RNAFutureGene ExpressionGene TranscriptionGenetic TranscriptionHIVHIV 1 associated neurocognitive disorderHIV associated neurocognitive deficitHIV associated neurocognitive impairmentHIV associated neurological diseaseHIV associated neurological disorderHIV incidenceHIV individualsHIV induced neurocognitive deficitHIV induced neurocognitive impairmentHIV infected individualsHIV infected personsHIV neurocognitive impairmentHIV peopleHIV positive individualsHIV positive peopleHIV-1HIV-1 associated neurocognitive deficitHIV-1 associated neurocognitive disorderHIV-1 associated neurocognitive impairmentHIV-1 incidenceHIV-1 infection incidenceHIV-IHIV-associated neurocognitive disorderHIV/AIDS incidenceHIV1HealthHippocampusHomeobox Protein PBX3Homologous Chemotactic CytokinesHumanHuman Immunodeficiency Virus Type 1Human Immunodeficiency Virus-1Human Immunodeficiency VirusesHuman immunodeficiency virus 1IQ DeficitImmunoblottingImpaired cognitionImpairmentIn vivo analysisIncrease lifespanIndividualInfumorphInhibitory SynapseInjectionsInjuryIntercrinesInvestigationKadianLAV-HTLV-IIILipid BindingLipidsLong-Term PotentiationLuciferase ImmunologicLuciferasesLymphadenopathy-Associated VirusLytotoxicityMS ContinMSirMacacaMacaqueMeasuresMediatingMediatorMedicationMessenger RNAMicroRNAsModalityModelingModern ManMolecularMorphiaMorphineMorphologyNerve CellsNerve DegenerationNerve UnitNeural CellNeuraxisNeurocognitive DeficitNeurocognitive Impairment in HIVNeurocognitive Impairment in HIV-1NeurocyteNeuron DegenerationNeuronal InjuryNeuronsNon-Polyadenylated RNANoncoding RNANontranslated RNAOpiate abuserOpiatesOpioidOpioid abuserOramorphOramorph SRPBX3PBX3 genePLWHPSD95PWHPathway interactionsPenetrationPeripheralPersonsPharmaceutical PreparationsPhenotypePotentiationPre-B-Cell Leukemia Transcription Factor 3ProteinsRNARNA ExpressionRNA Gene ProductsRNA based therapeuticsRNA based therapyRNA therapyRatRats MammalsRattusRegimenReporterResidualResidual stateRibonucleic AcidRodent ModelRoleRoxanolSAP90SIS cytokinesShort interfering RNASmall Interfering RNASourceSpinal ColumnSpineStatex SRSynapsesSynapticTestingTherapeuticTherapeutic InterventionTissuesTrans-Acting FactorsTrans-ActivatorsTransactivatorsTranscriptionTranscription ActivatorTranscription CoactivatorTranscription Factor CoactivatorTranscriptional Activator/CoactivatorTransfectionTransgenesTransgenic OrganismsTransmissionUntranslated RNAUpregulationValidationVertebral columnVesicleViral Gene ProductsViral Gene ProteinsViral ProteinsViremiaVirus-HIVWestern BlottingWestern Immunoblottinganti-retroviralantiretroviral therapyantiretroviral treatmentastrocytic gliaautophagybackbonebasebasesbehavior testbehavioral testbiomarker discoveryboost longevitybrain tissuechemoattractant cytokinechemokineco-morbidco-morbiditycognitive dysfunctioncognitive losscomorbiditycytokinecytotoxiccytotoxicitydevelopmentaldrug usedrug/agentefficacy testingelongating the lifespanenhance longevityexosomeextend life spanextend lifespanextend longevityextracellularextracellular vesiclesfoster longevityfunctional outcomesgephyrinhippocampalhuman immunodeficiency virus incidencehumanized micehumanized mouseimprove lifespanimprove longevityimprovedin vivoin vivo evaluationin vivo testingindividuals infected with HIVindividuals with HIVindividuals with human immunodeficiency virusinjuredinjuriesintelligence quotient deficitinterestintervention therapylife spanlifespanlifespan extensionlipid boundmRNAmiRNAmorphine administrationnano sizednanosizedneural degenerationneural inflammationneuro-AIDSneuro-HIVneuroAIDSneuroHIVneurocognitive declineneurocognitive impairmentneurodegenerationneurodegenerativeneuroinflammationneuroinflammatoryneuroligin 2neurological degenerationneuron injuryneuronalneuronal degenerationneuropathologicneuropathologicalneuropathologynon-medical opioid usenoncodingnonmedical opioid usenovelopiate consumptionopiate drug useopiate intakeopiate misuseopiate useopiate use disorderopioid consumptionopioid drug useopioid intakeopioid misuseopioid useopioid use disorderpathwaypeople infected with HIVpeople infected with human immunodeficiency viruspeople living with HIVpeople with HIVpeople with human immunodeficiency viruspharmacologicpostsynapticposttranscriptionalprolong lifespanprolong longevitypromote lifespanpromote longevityprotein blottingresponseshRNAshort hairpin RNAsiRNAsmall hairpin RNAsocial rolesupport longevitysynapsesynapse functionsynaptic functiontherapeutic RNAtherapeutic agent developmenttherapeutic developmenttransgenetransgenictransmission processuptakevalidationsvesicle releasevesicular releaseviraemiaviral sepsisvirus proteinvirusemia
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
Project Summary:
Currently, there are over 40 million people living with HIV-1 worldwide. Although combination antiretroviral
therapy (cART) has improved the health and lifespan of millions of those living with HIV-1, long-term use of
antiretrovirals coupled with limited penetration of some of these medications into the CNS, is often accompanied…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click